Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Midterm results of iCover stent grafts as bridging stent in fenestrated endovascular aortic repair.

Journal of vascular surgery cases and innovative techniques·2026
Same author

Endovascular Management of the Sutton-Kadir Syndrome: A Case Report.

Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists·2026
Same author

Long Term Follow Up of Bridging Stents is Necessary!

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery·2026
Same author

Consensus-Driven Vessel Preparation and Definitive Endovascular Treatment Strategies for Femoropopliteal Arterial Lesions Based on Plaque Morphology.

Journal of vascular and interventional radiology : JVIR·2026
Same author

Head-to-head comparison of two paclitaxel-coated balloons for femoropopliteal lesions: 3-year results from the BIOPACT RCT.

The Journal of cardiovascular surgery·2025
Same author

Dynetic-35 cobalt chromium balloon-expandable stent for iliac lesions: 12-month results of the BIONETIC-I multi-center study.

CVIR endovascular·2025

Related Experiment Video

Updated: Mar 1, 2026

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
06:28

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

4.4K

BeGraft Peripheral PMCF Study: 12-month results.

Koen Deloose1, Marc Bosiers2, Joren Callaert2

  • 1A.Z. Sint-Blasius, Dendermonde, Belgium - koen.deloose@telenet.be.

The Journal of Cardiovascular Surgery
|May 27, 2017
PubMed
Summary

Covered stents show high primary patency (94.4%) and freedom from revascularization (96.7%) at 12 months in aortoiliac lesions. This supports their use in vascular interventions.

More Related Videos

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

1.9K
The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

18.8K

Related Experiment Videos

Last Updated: Mar 1, 2026

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
06:28

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

4.4K
Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

1.9K
The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

18.8K

Area of Science:

  • Vascular Surgery
  • Interventional Cardiology
  • Medical Device Technology

Background:

  • Prospective, non-randomized BeGraft Peripheral Post-Market Clinical Follow-up (PMCF) study conducted in Belgium.
  • Reports 12-month follow-up data for a cohort of patients undergoing aortoiliac interventions.
  • Primary endpoint: primary patency at 12 months, defined by Duplex ultrasound and absence of target lesion revascularization (TLR).

Purpose of the Study:

  • To evaluate the 12-month efficacy of covered stents in treating aortoiliac lesions.
  • To assess primary patency and freedom from target lesion revascularization (TLR) in a real-world setting.

Main Methods:

  • 70 patients with TASC II Class A-D aortoiliac lesions were enrolled between June 2014 and March 2015.
  • Mean lesion length was 34.3 mm with an average stenosis of 83.16%.
  • Data analysis focused on primary patency and freedom from TLR at 12-month follow-up.

Main Results:

  • The overall primary patency rate at 12 months was 94.4%.
  • Freedom from target lesion revascularization (TLR) at 12 months was 96.7% for the entire patient cohort.

Conclusions:

  • The findings support the efficacy and positive clinical outcomes of using covered stents for aortoiliac interventions.
  • Further research with longer follow-up periods and more complex lesion subsets is warranted to expand understanding.